## Kirk E Evoy

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7618772/publications.pdf

Version: 2024-02-01

37 papers	943	15	30
	citations	h-index	g-index
37	37	37	1023
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Abuse and Misuse of Pregabalin and Gabapentin. Drugs, 2017, 77, 403-426.	10.9	295
2	Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs, 2021, 81, 125-156.	10.9	94
3	Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Research in Social and Administrative Pharmacy, 2019, 15, 953-958.	3.0	70
4	Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas. JAMA - Journal of the American Medical Association, 2018, 320, 1934.	7.4	53
5	Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. Substance Abuse: Research and Treatment, 2018, 12, 117822181880131.	0.9	42
6	Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction, 2021, 116, 1505-1511.	3.3	42
7	Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population. Pharmacotherapy, 2018, 38, 436-443.	2.6	37
8	Combination bupropion SR and varenicline for smoking cessation: a systematic review. American Journal of Drug and Alcohol Abuse, 2016, 42, 129-139.	2.1	33
9	Prevalence and characteristics of self-reported kratom use in a representative US general population sample. Journal of Addictive Diseases, 2020, 38, 506-513.	1.3	33
10	Impact of student pharmacist–led naloxone academic detailing at community pharmacies in Texas. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 81-86.	1.5	30
11	Considering the Potential Benefits of Over-the-Counter Naloxone. Integrated Pharmacy Research & Practice, 2021, Volume 10, 13-21.	1.5	20
12	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. Substance Abuse: Research and Treatment, 2019, 13, 117822181984420.	0.9	19
13	Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states. Drug and Alcohol Dependence, 2022, 237, 109518.	3.2	19
14	Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. Journal of the American Pharmacists Association: JAPhA, 2019, 59, 779-782.	1.5	18
15	Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy, 2021, 43, 1055-1064.	2.1	17
16	Pharmacist counseling when dispensing naloxone by standing order: A secret shopper study of 4 chain pharmacies. Journal of the American Pharmacists Association: JAPhA, 2021, 61, e94-e99.	1.5	17
17	Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. Innovations in Clinical Neuroscience, 2018, 15, 16-22.	0.1	17
18	Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. Journal of Clinical Pharmacology, 2021, 61, S89-S99.	2.0	15

#	Article	IF	CITATIONS
19	Aflibercept: Newly Approved for the Treatment of Macular Edema Following Central Retinal Vein Occlusion. Annals of Pharmacotherapy, 2013, 47, 819-827.	1.9	14
20	Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System. Drugs, 2017, 77, 1345-1351.	10.9	10
21	Ranibizumab: The First Vascular Endothelial Growth Factor Inhibitor Approved for the Treatment of Diabetic Macular Edema. Annals of Pharmacotherapy, 2013, 47, 811-818.	1.9	9
22	State-Level Approaches to Expanding Pharmacists' Authority to Dispense Naloxone May Affect Accessibility. JAMA Internal Medicine, 2019, 179, 1442.	5.1	7
23	Stop the Bleed: An Interprofessional Community Service Learning Project Assessing the Efficacy of Pharmacist-Led Hemorrhage Control Education for Laypersons. Disaster Medicine and Public Health Preparedness, 2021, 15, 271-276.	1.3	5
24	Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. Clinical Drug Investigation, 2021, 41, 245-253.	2.2	5
25	Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Mental Health Clinician, 2021, 11, 225-230.	1.0	5
26	Volunteering as medical staff at a diabetes summer camp as a component of a pharmacy residency program. Currents in Pharmacy Teaching and Learning, 2016, 8, 437-441.	1.0	3
27	Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System. Hospital Practice (1995), 2019, 47, 186-191.	1.0	3
28	National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. Journal of Substance Abuse Treatment, 2020, 119, 108141.	2.8	3
29	Authors' Reply to Bonnet et al. "Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update― Drugs, 2021, 81, 615-617.	10.9	3
30	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. Side Effects of Drugs Annual, 2017, , 359-372.	0.6	1
31	Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States. Substance Abuse: Research and Treatment, 2020, 14, 117822181989458.	0.9	1
32	Letter to the Editor: Comment on "Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth― Pain and Therapy, 2021, 10, 751-755.	3.2	1
33	A pilot study assessing the addition of a Quit and Win program to pharmacist-led intensive smoking cessation therapy in a predominantly underserved, minority population. Tobacco Prevention and Cessation, 2019, 5, 44.	0.4	1
34	Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System. Drugs - Real World Outcomes, 0, , .	1.6	1
35	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. Side Effects of Drugs Annual, 2018, 40, 447-461.	0.6	0
36	Reply. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e22-e23.	1.5	0

#	Article	IF	CITATIONS
37	Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone―[Response To Letter]. Integrated Pharmacy Research & Practice, 2021, Volume 10, 77-78.	1.5	O